Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women

Journal of Clinical Virology

Volumn 67, Issue , 2015, Pages 59-66

  Luttmer, Roosmarijn ^a   Berkhof, Johannes ^a   Dijkstra, Maaike G ^a   van Kemenade, Folkert J ^a,b   Snijders, Peter J F ^a   Heideman, Daniëlle A M ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Cytology; E7 mRNA; Genotyping; Human papillomavirus; Triage

Indexed keywords

VIRUS DNA; VIRUS MESSENGER RNA; MESSENGER RNA; PROTEIN E7; VIRUS RNA;

ADULT; ALGORITHM; ARTICLE; BIOPSY BRUSH; CERVICOVAGINAL SELF-SAMPLING DEVICE; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE E7; HUMAN TISSUE; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; OBSERVATIONAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS; ADOLESCENT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; CYTOLOGY; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84928894530     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.04.004     Document Type: Article

References (50)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189(September (1)):12-19.
2. Ronco G., Dillner J., Elfstrom K.M., Tunesi S., Snijders P.J., Arbyn M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2013, 383. November 1.
3. Dijkstra M.G., van N.D., Rijkaart D.C., van Kemenade F.J., Heideman D.A., Snijders P.J., et al.Primary hrH.P.V D.N.A. Testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol. Biomarkers Prev. 2014, 23(January (1)):55-63.
4. Rijkaart D.C., Berkhof J., van Kemenade F.J., Coupe V.M., Hesselink A.T., Rozendaal L., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int. J. Cancer 2012, 130(February (3)):602-610.
5. Fahey M.T., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am. J. Epidemiol. 1995, 141(April (7)):680-689.
6. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 2000, 132(May (10)):810-819.
7. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol. 2013, 121(April (4)):829-846.
8. de S.S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11(November (11)):1048-1056.
9. Castle P.E., Stoler M.H., Wright T.C., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011, 12(September (9)):880-890.
10. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 2005, 97(July (14)):1072-1079.
11. Andersson E., Karrberg C., Radberg T., Blomqvist L., Zetterqvist B.M., Ryd W., et al. Type-dependent E6/E7 mRNA expression of single and multiple high-risk human papillomavirus infections in cervical neoplasia. J. Clin. Virol. 2012, 54(May (1)):61-65.
12. Andersson S., Mints M., Weiderpass E., Johansson B. Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening. Curr. Pharm. Des. 2013, 19(8):1508-1515.
13. Benevolo M., Vocaturo A., Caraceni D., French D., Rosini S., Zappacosta R., et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J. Clin. Microbiol. 2011, 49(July (7)):2643-2650.
14. Benevolo M., Terrenato I., Mottolese M., Marandino F., Carosi M., Rollo F., et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control 2011, 22(June (6)):869-875.
15. Broccolo F., Fusetti L., Rosini S., Caraceni D., Zappacosta R., Ciccocioppo L., et al. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study. J. Med. Virol. 2013, 85(March (3)):472-482.
16. Burger E.A., Kornor H., Klemp M., Lauvrak V., Kristiansen I.S. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol. Oncol. 2011, 120(March (3)):430-438.
17. Cattani P., Siddu A., D'Onghia S., Marchetti S., Santangelo R., Vellone V.G., et al. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J. Clin. Microbiol. 2009, 47(July (7)):2136-2141.
18. Coquillard G., Palao B., Patterson B.K. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol. Oncol. 2011, 120(January (1)):89-93.
19. Cuschieri K., Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 2008, 17(October (10)):2536-2545.
20. Giorgi R.P., Benevolo M., Vocaturo A., Caraceni D., Ciccocioppo L., Frega A., et al. Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLoS One 2013, 8(2):e57600.
21. Halfon P., Benmoura D., Agostini A., Khiri H., Penaranda G., Martineau A., et al. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomarkers 2010, 7(3):133-139.
22. Hovland S., Muller S., Skomedal H., Mints M., Bergstrom J., Wallin K.L., et al. E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. Int. J. Oncol. 2010, 36(June (6)):1533-1539.
23. Liu T.Y., Xie R., Luo L., Reilly K.H., He C., Lin Y.Z., et al. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. J. Virol. Methods 2014, 196(February):120-125.
24. Oliveira A., Verdasca N., Pista A. Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia. J. Med. Virol. 2013, 85(July (7)):1235-1241.
25. Padalko E., Van R.L., Bamelis M., De M.A., Sturtewagen Y., Vastenavond H., et al. Prospective evaluation of E6/E7 mRNA detection by the NucliSENS Easy Q HPV assay in a stepwise protocol. J. Med. Virol. 2013, 85(July (7)):1242-1249.
26. Perez C.S., Inarrea F.A., Lamas Gonzalez M.J., Saran Diez M.T., Cid L.A., Alvarez Martin M.J., et al. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. J. Med. Virol. 2013, 85(June (6)):1063-1068.
27. Pierry D., Weiss G., Lack B., Chen V., Fusco J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch. Pathol. Lab. Med. 2012, 136(August (8)):956-960.
28. Rijkaart D.C., Heideman D.A., Coupe V.M., Brink A.A., Verheijen R.H., Skomedal H., et al. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J. Clin. Microbiol. 2012, 50(July (7)):2390-2396.
29. Salimovic-Besic I., Tomic-Cica A., Smailji A., Hukic M. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears. J. Virol. Methods 2013, 194(December (1-2)):222-228.
30. Sorbye S.W., Fismen S., Gutteberg T., Mortensen E.S. Triage of women with minor cervical lesions: data suggesting a test and treat approach for HPV E6/E7 mRNA testing. PLoS One 2010, 5(9):e12724.
31. Sorbye S.W., Arbyn M., Fismen S., Gutteberg T.J., Mortensen E.S. Triage of women with low-grade cervical lesions - HPV mRNA testing versus repeat cytology. PLoS One 2011, 6(8):e24083.
32. Sorbye S.W., Fismen S., Gutteberg T.J., Mortensen E.S., Skjeldestad F.E. HPV mRNA testing in triage of women with ASC-US cytology may reduce the time for CIN2+ diagnosis compared with repeat cytology. Curr. Pharm. Des. 2013, 19(8):1401-1405.
33. Varnai A.D., Bollmann M., Bankfalvi A., Speich N., Schmitt C., Griefingholt H., et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol. Rep. 2008, 19(February (2)):457-465.
34. Verdoodt F., Szarewski A., Halfon P., Cuschieri K., Arbyn M. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 2013, 121(December (12)):675-687.
35. Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30(November (Suppl. 5)):F55-F70.
36. Smelov V., Elfstrom K.M., Johansson A.L., Eklund C., Naucler P., Arnheim-Dahlstrom L., et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int. J. Cancer 2014, 136. July 19.
37. Hanselaar A.G. Criteria for organized cervical screening programs: special emphasis on The Netherlands program. Acta Cytol. 2002, 46(July (4)):619-629.
38. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 1995, 76(April (Pt 4)):1057-1062.
39. Jacobs M.V., de Roda Husman A.M., van den Brule A.J., Snijders P.J., Meijer C.J., Walboomers J.M. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J. Clin. Microbiol. 1995, 33(April (4)):901-905.
40. Schmitt M., Bravo I.G., Snijders P.J., Gissmann L., Pawlita M., Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 2006, 44(February (2)):504-512.
41. Anderson M.C. Premalignant and malignant squamous lesions of the cervix. Obstetrical and Gynaecological Pathology 2013, 292-297. Churchill Livingstone, New York. H. Fox, M. Wells (Eds.).
42. Cattani P., Zannoni G.F., Ricci C., D'Onghia S., Trivellizzi I.N., Di F.A., et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J. Clin. Microbiol. 2009, 47(December (12)):3895-3901.
43. Halfon P., Benmoura D., Agostini A., Khiri H., Martineau A., Penaranda G., et al. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J. Clin. Virol. 2010, 47(February (2)):177-181.
44. Molden T., Kraus I., Karlsen F., Skomedal H., Nygard J.F., Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 2005, 14(February (2)):367-372.
45. Molden T., Nygard J.F., Kraus I., Karlsen F., Nygard M., Skare G.B., et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 2005, 114(May (6)):973-976.
46. Heideman D.A., Hesselink A.T., van Kemenade F.J., Iftner T., Berkhof J., Topal F., et al. The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J. Clin. Microbiol. 2013, 51(November (11)):3653-3657.
47. Johnson D.C., Bhatta M.P., Smith J.S., Kempf M.C., Broker T.R., Vermund S.H., et al. Assessment of high-risk human papillomavirus infections using clinician- and self-collected cervical sampling methods in rural women from far western Nepal. PLoS One 2014, 9(6):e101255.
48. Chernesky M., Jang D., Gilchrist J., Elit L., Lytwyn A., Smieja M., et al. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. Sex Transm. Dis. 2014, 41(June (6)):365-368.
49. Ting J., Mugo N., Kwatampora J., Hill C., Chitwa M., Patel S., et al. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya. Sex Transm. Dis. 2013, 40(July (7)):584-589.
50. Castle P.E., Sideri M., Jeronimo J., Solomon D., Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 2007, 197(October (4)):356.